Development and Evaluation of a Topical Antifungal Gel of Crisaborole for Atopic Dermatitis

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin condition often complicated by secondary fungal infections. Crisaborole, a non-steroidal phosphodiesterase-4 (PDE4) inhibitor, has demonstrated anti-inflammatory properties in the treatment of mild to moderate AD. This study focuses on the development of a crisaborole -based antifungal gel designed to treat fungal complications commonly associated with AD. The gel formulation was evaluated for its physicochemical properties, antifungal efficacy, and skin compatibility. Results indicate that the crisaborole gel exhibits significant antifungal activity against Candida albicans and Malassezia furfur, microorganisms frequently associated with AD. Additionally, the gel showed good stability and excellent skin compatibility, making it a promising option for integrated treatment of AD with concurrent fungal infections.